Aptorum Group

Aptorum Group Current Liabilities

Delisted·Sep 22, 2026

The Current Liabilities of Aptorum Group (APM) as of Oct 29, 2026 is 4.59 M USD. In the previous year, Current Liabilities was 7.68 M USD — a change of -40.18% (lower).

Current Liabilities

4.59 MUSD

YoY

-40.18%

Last updated:

Current Liabilities of Aptorum Group is 2025 4.59 M USD. Current Liabilities of Aptorum Group was 2024 7.68 M USD. It decreases by -40.18% lower compared to the previous year.

The Aptorum Group Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
12.69 M USD
Jan 1, 2019
4.44 M USD
Jan 1, 2020
6.52 M USD
Jan 1, 2021
11.92 M USD
Jan 1, 2022
17.90 M USD
Jan 1, 2023
2.68 M USD
Jan 1, 2024
7.68 M USD
Jan 1, 2025
4.59 M USD
The Aptorum Group Current Liabilities history
YEARCurrent LiabilitiesYoY
4.59 MUSD-40.18%
7.68 MUSD+187.02%
2.68 MUSD-85.05%
17.90 MUSD+50.20%
11.92 MUSD+82.93%
6.52 MUSD+46.83%
4.44 MUSD-65.04%
12.69 MUSD+827.15%
1.37 MUSD+1,241.75%
102,048.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aptorum Group Stock analysis

What does Aptorum Group do? Aptorum Group Ltd. develops pharmaceutical products targeting unmet medical needs in infectious diseases, cancers, metabolic disorders, and neurology. The company leverages drug discovery platforms to screen approved drug molecules and microbiome-based research for metabolic treatments. It commercializes therapeutic assets through systematic screening and microbiome research, focusing on diseases like infectious conditions, cancer, and metabolic disorders. The company also pursues projects in gastroenterology, women’s health, and surgical robotics, alongside natural supplements for menopausal symptoms. Aptorum Group Ltd. generates revenue by advancing therapeutic and diagnostic projects across multiple disease areas. Its products include treatments for infectious diseases, cancers, and metabolic conditions, developed through drug discovery platforms and microbiome research. The company targets healthcare providers, pharmaceutical partners, and patients seeking innovative treatments for conditions with limited existing options. Segments include infectious disease therapies, cancer treatments, metabolic disorder solutions, and women’s health products. The company’s revenue streams come from the development and commercialization of therapeutic assets. It focuses on drug discovery through systematic screening of approved molecules and microbiome-based research for metabolic diseases. Projects in neurology, gastroenterology, and women’s health contribute to its product portfolio, alongside surgical robotics and natural supplements for menopausal symptoms. Aptorum Group Ltd. serves medical professionals and patients requiring novel treatments for underserved disease areas. Aptorum Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aptorum Group stock

Current Liabilities of Aptorum Group is 4.59 M USD in 2025.

Current Liabilities of Aptorum Group changed from 7.68 M USD to 4.59 M USD, representing a -40.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Aptorum Group since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Aptorum Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Aptorum Group

All Key Metrics — Aptorum Group